Diabetes Screening: Detection and Application of Saliva 1,5-anhydroglucitol by Liquid Chromatography-mass Spectrometry.

Like 0 Comment

Unlike other commonly used invasive blood glucose monitoring methods, saliva detection prevents patients from suffering the physical uneasiness. However, there are few studies on saliva 1,5-anhydroglucitol (1,5-AG) in patients with diabetes mellitus (DM).This study aimed to evaluate the effectiveness of saliva 1,5-AG in diabetes screening in a Chinese population.This was a population-based cross-sectional study. A total of 641 subjects without a valid diabetic history were recruited from September 2018 to June 2019. Saliva 1,5-AG was measured with liquid chromatography-mass spectrometry.Saliva 1,5-AG levels in DM subjects were lower than those in non-diabetes mellitus subjects (both P < 0.05). Saliva 1,5-AG was positively correlated with serum 1,5-AG and negatively correlated with blood glucose and glycated hemoglobin (HbA1c) (all P < 0.05). The optimal cutoff points of saliva 1,5-AG0 and 1,5-AG120 for diabetes screening were 0.436 g/mL (sensitivity: 63.58%, specificity: 60.61%) and 0.438 g/mL (sensitivity: 62.25%, specificity: 60.41%), respectively. Fasting plasma glucose (FPG) combined with fasting saliva 1,5-AG reduced the proportion of people who required an OGTT by 47.22% compared with FPG alone.Saliva 1,5-AG combined with FPG or HbA1c improved the efficiency of diabetes screening. Saliva 1,5-AG is robust in nonfasting measurements and a noninvasive and convenient tool for diabetes screening.

Click here to read the full article @ The Journal of clinical endocrinology and metabolism

Go to the profile of ClinOwl

ClinOwl

The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
1308 Contributions
1 Followers
0 Following

No comments yet.